Effects of polysaccharide sulfate on cardiovascular diseases induced by type 2 diabetes

Chinese Pharmacological Bulletin

Volumn 24, Issue 5, 2008, Pages 630-635

  Yu, Li Feng ^a   Zhao, Jin Sheng ^a   Yu, Long ^b   Zhao, Mei Mi ^a   Qi, He ^a   Li, Zhi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang First Pharmaceutical Factory ^*  (China)

Author keywords

Cardiovascular complications; Intercellular adhesion molecule; Nuclear factor kappa B (NF B); Polysaccharide sulfat; Tissue type plasminogen activator; Type 2 diabetic

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; METFORMIN; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYSACCHARIDE SULFATE; SODIUM CHLORIDE; STREPTOZOCIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

EID: 47649094707     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hechmidt A M, Yan S D, Wautier J L, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunctin in diabetic vasculopathy and atherosclerosis[J]. Cire Res, 1999,19,84(5):489-97.
2. Hills S A, Balkan B, Coppack S W, et al. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): Methodology and Objectives[J]. Diabetologia, 2004,47(5):556-70.
3. Pickup J C, Crook M A. Is type II diabetes mellitus a disease of the innate immune system[J]?. Diabetologia, 1998,41:1241-8.
4. Nesto R W, Rutter M K. Impact of the atherosclerotic process in patients with diabetes[J]. Acta Diabetol, 2002,39:22-8.
5. Tian A P, Guo S S, Shen Z F. Insulin resistant animal model established by high fat diet[J]. Chin Pharmacol Bull, 2006,22(3):267-9.
6. Zhang F, Ye C, Li G, et al. The rat model of Type 2 diabetic mellitus and its glycometabolism characters[J]. Exp Anim, 2003,52(5):401-7.
7. Baeuerle P A, Baltimore D. NF-κB: ten years after[J]. J Cell, 1996,87(1):13-20.
8. Shi C G, Hu G, Wang H. Nuclear factor-κB and the pathegenesis of the atherosclerosis[J]. Chin Pharmacol Bull, 2004,20(4):382-5.
9. Liu C M. Nuclear factor-Kappa B and atherosclerosis[J]. Med Rec, 2003,9(12):732-3.
10. Hamuro M, Polan J, Natarajan M, Mohan S. High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration[J]. Atherosclerosis, 2002,162:(2):277-87.
11. Dichtl W, Nilsson L, Concalves I, et al. Very low-density lipoprotein activates nuclear factor-kappa B in endothelial cells[J]. Circ Res, 1999,84(9):1085-94.
12. Xia P, Vadas M A, Barter P J, et al. High density lipoproteins (HDL) interrup the sphingosine kinase signaling pathway: a possible mechanism for protection anginst atherosclerosis by HDL[J]. J Biol Chem, 1999,274(6):33143-7.
13. Davies M J, Cordon J L, Gearing A J, et al. The expression of the adhension molecules ICAM-1 VCAM-1 PECAM, and E-selectin in human arteriosclerosis[J]. J Pathol, 1993,171(3):223-9.
14. Sobel B E. Fibrinolysis and diabetes[J]. Front Biosci, 2003,8:d1085-92.
15. Sobel B E, Taatjes D J, Schneider D J. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2003,23(11):1979-89.